Background: Renal cell carcinoma with sarcomatoid dedifferentiation represents a rare
histological entity characterized by aggressive behavior, limited efficacy of tyrosine kinase …

Although the optimal selection criteria and timing for CN remains to be established for
patients with mRCC in the immunotherapy era, the available body of evidence underscores …

Importance The adverse effects of COVID-19 containment policies disrupting child mental
health and sleep have been debated. However, few current estimates correct biases of …

Background: Low-dose prasugrel (3.75 mg) is used as maintenance therapy for
percutaneous coronary intervention; however, data on long-term outcomes are scarce …

Immunotherapy-based systemic treatment (ST) is the standard of care for most patients
diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) …

Up to 30% of adrenocortical carcinoma (ACC) patients have metastasised disease upon
initial presentation, and systemic treatments currently fail to sufficiently improve survival …

Cytoreductive nephrectomy (CN) combined with systemic therapy is commonly used to treat
metastatic clear-cell renal cell carcinoma (mccRCC). However, prognostic models for these …

Substantial changes have occurred in the systemic treatment paradigm for metastatic renal
cell carcinoma (mRCC) with the development of immune checkpoint inhibitors (ICIs)[1]. To …

Abstract Background/Objectives: The presence of paraneoplastic syndromes (PNS) in
patients with renal cell carcinoma (RCC) is associated with worse survival; however, little is …

Renal cell carcinoma accounts for a significant proportion of cancer diagnoses in
Canadians. Over the past several years, the management of renal cell cancers has …